Methotrexate Reactions 1680, p220 - 2 Dec 2017 Alopecia areata: case report An 11-year-old girl developed alopecia areata (AA) during treatment with methotrexate. The girl, who had a history of crohn’s disease (CD), was initially started on induction therapy with prednisolone. A slow tapering of prednisolone was done and she started receiving maintenance therapy with azathioprine. After a few doses of azathioprine, she developed an allergic reaction characterised by fever and skin eruption, requiring its discontinuation. The prednisolone slowly tapered and discontinued. She continued to be asymptomatic without reoccurrence of fever or any other symptoms. Seven months later, her underlying CD was found to be active. The prednisolone was restarted followed by a weekly SC injections of methotrexate 15 mg/m . The prednisolone was again discontinuation. Fifteen months after commencing the methotrexate therapy, she developed localised areas of alopecia. She was diagnosed with AA based on a characteristic ophiasis means snake like pattern extending from her occipital to parietal and frontotemporal scalp areas. There was also appearance of localised spots of hair loss in her eye lashes. The girl was treated with intralesional injections of triamcinolone which resulted in 90% hair regrowth. Six months later, the alopecia recurred and she had even more hair loss. A serial injections of triamcinolone every four weeks for three months lead to 75% hair regrowth. Author comment: "Our patient developed AA while on maintenance treatment with [methotrexate]. While it has been linked to alopecia in [inflammatory bowel disease] patients in some reports, no study has specifically examined [methotrexate] as a cause of AA." Sankararaman S, et al. Alopecia Areata in an Adolescent with Inflammatory Bowel Disease. Clinical Pediatrics 56: 1350-1352, No. 14, 2017. Available from: URL: - USA 803286061 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 Reactions Weekly Springer Journals


Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
1 page

Loading next page...
1 Page
Springer International Publishing
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
Publisher site
See Article on Publisher Site


You’re reading a free preview. Subscribe to read the entire article.

DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches


Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.



billed annually
Start Free Trial

14-day Free Trial